Developing Innovative Cancer Immunotherapies

Learn about our pipeline

Clinical Trials

Developing innovative internally discovered small molecule drug candidates as well as antibody candidates that target immuno-oncology pathways

learn more

We’re Hiring!

Arcus Biosciences is an exciting young company founded on the vision of creating new cancer therapeutics through the translation of unexploited insights in immunology.

learn more


Adenosine dreams fueling new approaches in cancer; Arcus embarks on phase I

By Randy Osborne, Staff Writer

Although Merck & Co. Inc. continues to chalk up investor-pleasing sales with Keytruda (pembrolizumab) and Bristol-Myers Squibb Co. (BMS) keeps doing well with Opdivo (nivolumab), researchers have yet to strike upon the best combinations with other agents.

Keep Reading


Phase 1
Phase 1b Dose Esc.

AB928 (A2aR/A2bR Antagonist) ⇓

AB928 + AB122 (anti-PD-1)
AB928 + Chemotherapy

AB680 (Small Molecule CD73i) ⇓

AB680 (IV)
Phase 1 in HVs initiated
AB680 (oral)

Antibody Programs ⇓

AB122 (anti-PD-1 Antibody)
Enrolling in solid tumors
AB154 (anti-TIGIT Antibody)
Enrolling in solid tumors

Other Small Molecules ⇓

AB745 (A2aR Antagonist)
Arginase inhibitor
Lead optimization

Arcus has significant expertise in immunology, medicinal chemistry, biochemistry, enzymology, pharmacology, and structural biology.

Meet Our Leadership